Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 6, 2015, Pages 967-977

  Young, G ^a   Mahlangu, J ^b   Kulkarni, R ^c   Nolan, B ^d   Liesner, R ^e   Pasi, J ^f   Barnes, C ^g   Neelakantan, S ^h   Gambino, G ^h   Cristiano, L M ^h   Pierce, G F ^h   Allen, G ^h  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g ROYAL CHILDREN'S HOSPITAL   (Australia)

^h BIOGEN   (United States)

Author keywords

Children; Coagulation factor VIII; Hemophilia A; Prophylaxis; Recombinant fusion proteins

Indexed keywords

BLOOD CLOTTING FACTOR 8; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8 FC FUSION PROTEIN; UNCLASSIFIED DRUG; COAGULATING AGENT; FACTOR VIII-FC FUSION PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

AGE; ANNUALIZED BLEEDING RATE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; BLEEDING; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; CHILD; COUGHING; DIARRHEA; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EAR INFECTION; EPILEPSY; ERYTHEMA; FAMILY HISTORY; FATIGUE; FEVER; GENOTYPE; HEAD INJURY; HEADACHE; HEMOPHILIA A; HUMAN; JOINT SWELLING; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POLLEN ALLERGY; PRIORITY JOURNAL; PROPHYLAXIS; RHINOPHARYNGITIS; RHINORRHEA; TONSILLITIS; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; VOMITING; AUSTRALIA; BLOOD; CHINA; CLINICAL TRIAL; DRUG ADMINISTRATION; EUROPE; FEMALE; HALF LIFE TIME; HEMARTHROSIS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; NORTH AMERICA; PRESCHOOL CHILD; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SOUTH AFRICA; TREATMENT OUTCOME;

AGE FACTORS; ANTIBODIES, NEUTRALIZING; AUSTRALIA; CHILD; CHILD, PRESCHOOL; CHINA; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; EUROPE; FACTOR VIII; FEMALE; HALF-LIFE; HEMARTHROSIS; HEMOPHILIA A; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; INFUSIONS, INTRAVENOUS; MALE; NORTH AMERICA; RECOMBINANT FUSION PROTEINS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 84930179981     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12911     Document Type: Article

References (43)

1. Manco-Johnson MJ, Riske B, Kasper CK. Advances in care of children with hemophilia. Semin Thromb Hemost 2003; 29: 585-94.
2. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
4. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
5. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding), 2007. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57{00AMP00}contentid=1007. Accessed 30 January 2015.
6. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
7. Zappa S, McDaniel M, Marandola J, Allen G. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia 2012; 18: e140-53.
8. Fogarty PF. Biological rationale for new drugs in the bleeding disorders pipeline. Hematology Am Soc Hematol Educ Program 2011; 2011: 397-404.
9. Bjorkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, Casey K, Fischer K, Blanchette VS, Collins PW. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-18.
10. Peters RT, Toby G, Lu Q, Liu T, Kulman JD, Low SC, Bitonti AJ, Pierce GF. Biochemical and functional characterization of a recombinant monomeric factor VIII Fc fusion protein. J Thromb Haemost 2013; 11: 132-41.
11. Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao SW, Lencer WI, Pierce GF, Blumberg RS. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 2013 [Epub ahead of print].
12. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2013; 123: 317-25.
13. Gouw SC, van den Berg HM, Oldenburg J, Astermark J, de Groot PG, Margaglione M, Thompson AR, van Heerde W, Boekhorst J, Miller CH, le Cessie S, van der Bom JG. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119: 2922-34.
14. Margaglione M, Castaman G, Morfini M, Rocino A, Santagostino E, Tagariello G, Tagliaferri AR, Zanon E, Bicocchi MP, Castaldo G, Peyvandi F, Santacroce R, Torricelli F, Grandone E, Mannucci PM; the AICE-Genetics Study Group. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica 2008; 93: 722-8.
15. European Medicines Agency. Guideline on clinical investigation of recombinant and human plasma-derived factor VIII products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109692.pdf. Accessed 5 June 2014.
16. United States Food and Drug Administration. Guidance for industry: assay development for immunogenicity testing of therapeutic proteins. December 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf. Accessed 5 June 2014.
17. Baxter Healthcare Corporation. Advate [antihemophilic factor (recombinant), plasma/albumin-free method] (package insert). July 2012. http://www.advate.com/assets/pdf/advate_iri_pi.pdf. Accessed 17 July 2014.
18. Kulkarni R, Karim FA, Glamocanin S, Janic D, Vdovin V, Ozelo M, Rageliene L, Carboni E, Laguna P, Dobaczewski G, Seremetis S, Lindblom A, Santagostino E. Results from a large multinational clinical trial (guardian3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013; 19: 698-705.
19. Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031-7.
20. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
21. Khawaji M, Astermark J, Akesson K, Berntorp E. Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis. Haemophilia 2010; 16: 495-501.
22. Ross C, Goldenberg NA, Hund D, Manco-Johnson MJ. Athletic participation in severe hemophilia: bleeding and joint outcomes in children on prophylaxis. Pediatrics 2009; 124: 1267-72.
23. DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
24. Gringeri A, Tagliaferri A, Tagariello G, Morfini M, Santagostino E, Mannucci P, ReFacto ASG. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol 2004; 126: 398-404.
25. Xi M, Makris M, Marcucci M, Santagostino E, Mannucci PM, Iorio A. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost 2013; 11: 1655-62.
26. Valentino LA, Negrier C, Kohla G, Tiede A, Liesner R, Hart D, Knaub S. The first recombinant FVIII produced in human cells-an update on its clinical development programme. Haemophilia 2014; 20(Suppl. 1): 1-9.
27. Batlle J, Gomez E, Rendal E, Torea J, Loures E, Couselo M, Vila P, Sedano C, Tusell X, Magallon M, Quintana M, Gonzalez-Boullosa R, Lopez-Fernandez MF. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol 1996; 72: 321-6.
28. Klintman J, Hillarp A, Donfield S, Berntorp E, Astermark J. Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A. Haemophilia 2013; 19: 106-12.
29. Krudysz-Amblo J, Parhami-Seren B, Butenas S, Brummel-Ziedins KE, Gomperts ED, Rivard GE, Mann KG. Quantitation of anti-factor VIII antibodies in human plasma. Blood 2009; 113: 2587-94.
30. Dazzi F, Tison T, Vianello F, Radossi P, Zerbinati P, Carraro P, Poletti A, Girolami A. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 1996; 93: 688-93.
31. Klintman J, Hillarp A, Berntorp E, Astermark J. Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy. Br J Haematol 2013; 163: 385-92.
32. van Dijk K, van der Bom JG, Lenting PJ, de Groot PG, Mauser-Bunschoten EP, Roosendaal G, Grobbee DE, van den Berg HM. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005; 90: 494-8.
33. Bjorkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 989-98.
34. Bjorkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM, Advate Clinical Program G, Collins PW. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010; 8: 730-6.
35. Terraube V, O'Donnell JS, Jenkins PV. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia 2010; 16: 3-13.
36. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, Bertomoro A, Daidone V, Pagnan A, Casonato A. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111: 3540-5.
37. Kumar S, Liu T, Kulman JD, Chang P-Y, Ding S, Bardan S, Moore N, Patarroyo-White S, Pierce GF, Schellenberger V, Jiang H, Mei B, Peters RT, editors. Effect of unstructured polypeptide insertions on the recombinant expression of human factor VIII. Presented at: International Society on Thrombosis and Haemostasis-24th Congress; June 29-July 4, 2013; Amsterdam, The Netherlands. J Thromb Haemost 2013; 11: 711.
38. Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, Liu T, Zhang X, Severs J, Newgren J, Chen J, Gu JM, Subramanyam B, Fournel MA, Pierce GF, Murphy JE. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
39. Tiede A, Brand B, Fischer R, Kavakli K, Lentz SR, Matsushita T, Rea C, Knobe K, Viuff D. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-man trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11: 670-8.
40. Fogarty PF, Powell JS, Kruse-Jarres R, Mahlangu J, Perry D, McRae S, Potts J, Li S, Brennan A, Pierce GF, editors. Analysis of baseline characteristics and 5-day dosing interval with rFVIIIFc in the phase 3 A-LONG study. Presented at: Thrombosis and Hemostasis Summit of North America; April 10-12, 2014; Chicago, IL, USA. Am J Hematol 2014; 89: E35.
41. DiMichele DM, Blanchette V, Berntorp E. Clinical trial design in haemophilia. Haemophilia 2012; 18(Suppl. 4): 18-23.
42. McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, Patel N, Tuddenham EG, Christophe OD, McVey JH, Waddington S, Nienhuis AW, Gray JT, Fagone P, Mingozzi F, Zhou SZ, High KA, Cancio M, Ng CY, Zhou J, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 2013; 121: 3335-44.
43. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-65.